Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CAR19-BCMA CAR-T cells (Affiliated Hospital to Academy of Military Medical Sciences)
- Development stage
- Phase 1
- Lead developer
- Academy of Military Medical Sciences
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
CAR19-BCMA CAR-T cells (Affiliated Hospital to Academy of Military Medical Sciences) is an investigational dual-targeted chimeric antigen receptor (CAR) T-cell therapy designed to treat relapsed or refractory plasma cell neoplasms. The therapy utilizes autologous T cells genetically modified to simultaneously target two distinct antigens: B-lymphocyte antigen CD19 and B-cell maturation antigen (BCMA). While BCMA is a well-validated target for multiple myeloma, the addition of CD19 targeting is intended to address potential antigen escape and target a broader range of malignant cells, including those with lower BCMA expression or progenitor-like qualities. Developed by the Affiliated Hospital to the Academy of Military Medical Sciences, this cell therapy is currently being evaluated in early-phase clinical trials for indications including multiple myeloma, plasma cell leukemia, and systemic light chain amyloidosis.
- Other names
- CAR19-BCMA dual-target CAR-T cell therapyCAR-19-BCMA dual-target CAR-T cell therapyCAR 19-BCMA dual-target CAR-T cell therapy
02
Targets
CD19 (B lymphocyte antigen CD19)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on CAR19-BCMA CAR-T cells (Affiliated Hospital to Academy of Military Medical Sciences).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CAR19-BCMA CAR-T cells (Affiliated Hospital to Academy of Military Medical Sciences).